CAR-T and Bispecifics Move Closer to Home: Outpatient and Community Models at ASH 2026

Several abstracts focus on delivering CAR-T and bispecific therapy outside the traditional inpatient academic setting.

• Abstract 156 (Oral, 10:45–11:00 AM): “Projected cost savings of a prophylactic tocilizumab-enabled outpatient bispecific initiation pathway in multiple myeloma” (Singh).
• Abstract 310 (Oral, 2:45–3:00 PM): Patient and caregiver experience in an outpatient CAR-T program supported by remote patient monitoring.
• Abstract 311 (Oral, 3:00–3:15 PM): Outpatient liso-cel remote patient monitoring (Battiwalla).
• Abstract 2251 (Poster): Outpatient teclistamab plus prophylactic oral dexamethasone, Phase 2 OPTEC arm C (NCT05972135).
• Abstract 2209 (Poster): “Unplanned hospitalization during outpatient step-up dosing of bispecific antibodies in multiple myeloma” (Awadallah).
• Abstract 2284 (Poster): “Expanding bispecific antibody access in a community health system” (Hunter).
• Abstract 308 (Oral, 2:15–2:30 PM): “CAR T-cell therapy in Appalachia: A hub-and-spoke model of care…” (DeCicco).

Most of the oral abstracts above sit in Session 902 (Health Services and Quality Improvement: Lymphoid Malignancies). Operations and site-readiness teams may find that session worth blocking time for.